CVM Quote, Financials, Valuation and Earnings

IGC Pharma has a net margin of -- compared to CEL-SCI's net margin of -711.67%. CEL-SCI's return on equity of -- beat IGC Pharma's return on equity of -116.24%.

CEL-SCI has a consensus price target of $7.40, signalling upside risk potential of 2334.21%. On the other hand IGC Pharma has an analysts' consensus of $3.88 which suggests that it could grow by 1057.41%. Given that CEL-SCI has higher upside potential than IGC Pharma, analysts believe CEL-SCI is more attractive than IGC Pharma.

CEL-SCI has a beta of 0.666, which suggesting that the stock is 33.414% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.213, suggesting its more volatile than the S&P 500 by 21.346%.

CEL-SCI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

CEL-SCI quarterly revenues are --, which are smaller than IGC Pharma quarterly revenues of $257K. CEL-SCI's net income of -$7.1M is lower than IGC Pharma's net income of -$1.8M. Notably, CEL-SCI's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI is -- versus 19.69x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to CEL-SCI's net margin of -49.65%. CEL-SCI's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

CEL-SCI has a consensus price target of $7.40, signalling upside risk potential of 2334.21%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 34.9%. Given that CEL-SCI has higher upside potential than NovaBay Pharmaceuticals, analysts believe CEL-SCI is more attractive than NovaBay Pharmaceuticals.

CEL-SCI has a beta of 0.666, which suggesting that the stock is 33.414% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.726, suggesting its less volatile than the S&P 500 by 27.362%.

CEL-SCI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

CEL-SCI quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. CEL-SCI's net income of -$7.1M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, CEL-SCI's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -- compared to CEL-SCI's net margin of 18.02%. CEL-SCI's return on equity of -- beat Protalix BioTherapeutics's return on equity of -29.54%.

CEL-SCI has a consensus price target of $7.40, signalling upside risk potential of 2334.21%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 547.32%. Given that CEL-SCI has higher upside potential than Protalix BioTherapeutics, analysts believe CEL-SCI is more attractive than Protalix BioTherapeutics.

CEL-SCI has a beta of 0.666, which suggesting that the stock is 33.414% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.724, suggesting its less volatile than the S&P 500 by 27.611%.

CEL-SCI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

CEL-SCI quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $18M. CEL-SCI's net income of -$7.1M is lower than Protalix BioTherapeutics's net income of $3.2M. Notably, CEL-SCI's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 121.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI is -- versus 3.85x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to CEL-SCI's net margin of -2357.27%. CEL-SCI's return on equity of -- beat Palatin Technologies's return on equity of --.

CEL-SCI has a consensus price target of $7.40, signalling upside risk potential of 2334.21%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 785.18%. Given that CEL-SCI has higher upside potential than Palatin Technologies, analysts believe CEL-SCI is more attractive than Palatin Technologies.

CEL-SCI has a beta of 0.666, which suggesting that the stock is 33.414% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.793, suggesting its less volatile than the S&P 500 by 20.66%.

CEL-SCI has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CEL-SCI pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

CEL-SCI quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. CEL-SCI's net income of -$7.1M is lower than Palatin Technologies's net income of -$2.4M. Notably, CEL-SCI's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CEL-SCI is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.